January 1, 1997Thrombosis and Haemostasis
Clinical Trials with Glycoprotein IIb/IIIa Receptor Antagonists in Acute Coronary Syndromes
Population
Patients with acute coronary syndromes
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
GP IIb/IIIa antagonists should not yet alter ACS medical management; large RCTs needed to resolve uncertainty.
Structured PICO
P
Population
Patients with acute coronary syndromes
I
Intervention
Glycoprotein IIb/IIIa receptor antagonists
The potential value of Glycoprotein IIb/IIIa receptor antagonists for the medical treatment of acute coronary syndromes remains uncertain pending the results of large randomized trials.
Cite This Study
Frans Van de Werf (1997) studied this question.